Table 3.
Number of studies and cardiovascular outcomes reported, by country
| Country | Income statusa | Studies | Patients | Stroke | MI | Angina | CHF | Atherosclerosis | CAD | CVD (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Australia | High | 3b | 1569 | 7.7% | NR | NR | NR | NR | 21.8% | 29.4 |
| Belgium | High | 1 | 711 | 8.0% | NR | NR | NR | NR | 22.0% | 30.0 |
| Brazil | Upper middle | 2 | 537 | 5.5% | NR | NR | 4.2% | NR | 22.6% | 27.5 |
| Cameroon | Low middle | 1 | 132 | 5.0% | NR | NR | NR | NR | 23.6% | 28.6 |
| China | Upper middle | 5 | 39,934 | 15.2% | NR | NR | 4.3% | 30.5% | 17.0% | 28.4 |
| France | High | 1 | 987 | 15.3% | NR | NR | 9.1% | NR | 29.5% | 53.9 |
| India | Low middle | 3b | 1656 | 3.1% | NR | NR | NR | NR | 29.4% | 42.6 |
| Indonesia | Low middle | 1 | 400 | 10.8% | NR | NR | NR | NR | 28.8% | 39.6 |
| Iraq | Upper middle | 1 | 1079 | NR | NR | NR | NR | NR | NR | 16.0 |
| Ireland | High | 1 | 309 | 5.2% | NR | NR | NR | NR | 17.8% | 23.0 |
| Italy | High | 5 | 19,869 | 2.4% | 6.2% | NR | NR | NR | 11.1% | 14.8 |
| Korea | High | 2 | 654 | 20.3% | NR | NR | NR | 21.5% | 37.0% | 47.2 |
| Mexico | Upper middle | 1 | 160 | NR | NR | NR | 57.5% | NR | NR | 57.5 |
| Netherlands | High | 3 | 899 | 6.1% | NR | NR | 30.6% | 33.0% | 28.2% | 44.5 |
| Portugal | High | 1 | 3215 | 5.0% | NR | NR | NR | NR | 12.0% | 17.0 |
| Qatar | High | 1 | 180 | NR | NR | NR | NR | NR | 31.7% | 31.7 |
| Russian Federation | Upper middle | 1 | 3,060,517 | 4.2% | 3.4% | NR | NR | NR | 13.4% | 21.0 |
| Saudi Arabia | High | 2 | 2700 | 7.1% | 11.4% | NR | NR | NR | 23.1% | 30.0 |
| Scotland | High | 3b | 351,592 | NR | NR | NR | NR | NR | 19.7% | 19.7 |
| Spain | High | 7 | 430,855 | 8.0% | 20.2% | NR | 30.3% | NR | 13.6% | 29.8 |
| Sweden | High | 3 | 453,791 | 10.3% | 9.3% | 14.6% | 9.5% | NR | NR | 31.3 |
| Switzerland | High | 1 | 83 | 15.7% | NR | NR | NR | NR | 33.7% | 49.4 |
| Thailand | Upper middle | 1 | 1505 | 2.5% | NR | NR | NR | NR | NR | 2.5 |
| UK | High | 1 | 2733 | 7.9% | NR | NR | NR | NR | 34.5% | 42.4 |
| USA | High | 7 | 170,803 | 10.9% | 13.6% | 17.2% | 15.5% | NR | 28.1% | 44.0 |
| 16 countries | High | 42 | 1,440,950 | 9.3% | 12.1% | 15.9% | 19.0% | 27.3% | 24.3% | 33.6 |
| 6 countries | Upper middle | 11 | 3,103,732 | 6.9% | 3.4% | 22.0% | 30.5% | 17.7% | 25.5 | |
| 3 countries | Low middle | 5 | 2188 | 6.3% | 27.3% | 36.9 | ||||
| 0 countries | Low | 0 | 0 | |||||||
| 25 countries | Overall | 58 | 4,546,870c | 8.4% | 10.7% | 15.9% | 20.1% | 28.3% | 23.7% | 32.1 |
CAD coronary artery disease (also reported as coronary heart disease or ischemic heart disease), CHF congestive heart failure, CVD cardiovascular disease, MI myocardial infarction, NR not reported
aWorld Bank status [117] based on Gross National Income per capita per annum (in USD) as of 01 July, 2016: Low < $1025; Low middle = $1026–$4035; Upper middle = $4036–$12,475; High > $12,476. Country status extracted from World Bank Database [118]
bA study reports two separate analyses within the same paper. In total there are 58 studies across 55 articles
cStudy evaluated patients from multiple countries and therefore is not included in this table. Thus, there are 4,546,870 patients across 55 studies